Daniel Flora, Medical Oncologist and Medical Director of Oncology Research at St. Elizabeth Healthcare, shared a post on LinkedIn:
“We now have more than 10 years of follow-up data on immunotherapy in metastatic melanoma.
For patients diagnosed with stage IV melanoma today, treatment with immune checkpoint inhibitors will lead to long-term survival in more than half of patients, including those with brain metastases, with many long-term survivors off therapy.
Among patients who achieve a response and remain in remission for three years, the likelihood of being cancer-free at 10 years is approximately 97 percent, an outcome that begins to approach what we would consider a functional cure in oncology. Even as someone who treats this disease every day, I still find these outcomes hard to believe.”
More posts featuring Daniel Flora.